X4 Pharmaceuticals, Inc.
NASDAQ:XFOR · NASDAQ Capital Market
+$0.12 today
Vol 0.21M · Avg 0.40M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $216.9M |
| Short-term Investments | $16.8M |
| Receivables | $1.1M |
| Inventory | $4.6M |
| Other Current | $2.5M |
| Total Current Assets | $242.0M |
| PP&E (Net) | $1.2M |
| Goodwill | $17.4M |
| Intangible Assets | $9.1M |
| Other Non-current | $704.0K |
| Total Non-current Assets | $28.3M |
| Total Assets | $270.3M |
Analysis
Selected assets total $270.3M for Latest. The largest visible component is Cash & Equivalents at $216.9M, about 80.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $217.0M +289.7% | $55.7M -43.9% | $99.2M -18.5% | $121.7M +48.8% | $81.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $35.9M -22.5% | $46.4M +209.1% | $15.0M | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $573.0K -66.5% | $1.7M +204.3% | $562.0K -51.2% | $1.2M +54.2% | $747.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $4.5M +59.0% | $2.8M | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3.5M -36.9% | $5.6M -23.4% | $7.3M +25.7% | $5.8M +8.7% | $5.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $261.6M +133.2% | $112.2M -8.1% | $122.1M -5.1% | $128.7M +46.4% | $87.9M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $1.6M -67.1% | $4.8M -24.3% | $6.4M -23.3% | $8.3M -18.5% | $10.2M | $1.2B | $1.5B | $687.8M |
| Goodwill | $17.4M +0.0% | $17.4M +0.0% | $17.4M +0.0% | $17.4M +0.0% | $17.4M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $9.3M -7.5% | $10.0M | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 -100.0% | $1.3M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $692.0K -66.7% | $2.1M +44.8% | $1.4M +17.2% | $1.2M +204.7% | $402.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $28.9M -15.7% | $34.3M +36.1% | $25.2M -6.4% | $26.9M -8.2% | $29.3M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $290.5M +98.3% | $146.4M -0.6% | $147.3M -5.4% | $155.6M +32.8% | $117.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.7M -33.9% | $8.6M -3.6% | $8.9M +15.0% | $7.8M +81.6% | $4.3M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 -100.0% | $1.3M -29.7% | $1.9M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $464.0K | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $4.3M -67.0% | $13.1M +59.3% | $8.2M +24.3% | $6.6M +168.7% | $2.5M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $25.8M -21.7% | $32.9M +43.8% | $22.9M +2.4% | $22.3M +59.2% | $14.0M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $76.3M +1.1% | $75.4M +38.2% | $54.6M +68.9% | $32.3M -2.5% | $33.1M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $621.0K | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $1.5M -89.7% | $14.6M -9.5% | $16.1M -30.8% | $23.3M +2721.3% | $826.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $78.4M -14.2% | $91.4M +24.7% | $73.3M +23.8% | $59.2M +52.8% | $38.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $104.2M -16.2% | $124.3M +29.3% | $96.2M +17.9% | $81.5M +54.5% | $52.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $91.0K +1416.7% | $6.0K -96.4% | $167.0K +36.9% | $122.0K +335.7% | $28.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$594.6M -15.4% | -$515.4M -7.8% | -$477.9M -26.9% | -$376.7M -33.2% | -$282.9M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$109.0K +10.7% | -$122.0K -2.5% | -$119.0K +0.0% | -$119.0K +0.0% | -$119.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $186.3M +741.1% | $22.1M -56.7% | $51.1M -31.0% | $74.1M +15.0% | $64.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $77.3M -1.0% | $78.1M +34.0% | $58.3M +51.7% | $38.4M -3.4% | $39.8M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$139.8M -724.3% | $22.4M +154.7% | -$40.9M +50.9% | -$83.3M -98.3% | -$42.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$215.30M
Mersana Therapeutics, Inc.
MRSN
$145.36M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$57.43M
Kezar Life Sciences, Inc.
KZR
$53.86M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$32.97M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Skye Bioscience, Inc.
SKYE
$27.67M
Senti Biosciences, Inc.
SNTI
$25.24M
Tempest Therapeutics, Inc.
TPST
$5.60M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does XFOR have?
X4 Pharmaceuticals, Inc. (XFOR) reported $217.05M in cash and equivalents in fiscal 2025.
How much debt does XFOR carry?
X4 Pharmaceuticals, Inc. (XFOR) reported $77.28M of total debt, with net debt of -$139,764,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.